Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | FYN | P06241 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | MMP12 | P39900 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31301918 | 1.00 | CYP2B6 (0.42) | CYP2B6CYP1A1CYP1A2CA1CA9 | |
| SCHEMBL28185909 | 0.80 | MET (0.40) | CYP2B6CYP1A1CYP1A2CA1CA9 | |
| SCHEMBL30663208 | 0.76 | CYP2B6 (0.42) | CYP2B6CYP1A1CYP1A2CA1CA9 | |
| SCHEMBL12043463 | 0.76 | CYP2B6 (0.42) | CYP2B6CYP1A1CYP1A2CA1CA9 | |
| SCHEMBL27707071 | 0.76 | CYP2B6 (0.42) | CYP2B6CYP1A1CYP1A2CA1CA9 | |
| SCHEMBL5544992 | 0.76 | CYP2B6 (0.42) | CYP2B6CYP1A1CYP1A2CA1CA9 | |
| SCHEMBL2009438 | 0.76 | CYP2B6 (0.42) | CYP2B6CYP1A1CYP1A2CA1CA9 | |
| SCHEMBL11192919 | 0.76 | CYP2B6 (0.42) | CYP2B6CYP1A1CYP1A2CA1CA9 | |
| SCHEMBL277664 | 0.76 | CYP2B6 (0.46) | CYP2B6CYP1A1CYP1A2CA1CA9 | |
| SCHEMBL28070824 | 0.76 | CYP2B6 (0.40) | CYP2B6CYP1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111417396-A | Methods of treating cancer with small molecule NF-kB inhibitors | 免疫目标公司 | 2020-07-14 | — | — | CN | disclosed |
| US-20140135359-A1 | METHODS OF DESIGNING, PREPARING, AND USING NOVEL PROTONOPHORES | MARTINEAU LOUIS C (CA) | 2014-05-15 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7789958-B2 | Non-toxic corrosion-protection pigments based on manganese | UNIVERSITY OF DAYTON (US) | 2010-09-07 | — | — | US | disclosed |
| US-7422793-B2 | Non-toxic corrosion-protection rinses and seals based on rare earth elements | UNIVERSITY OF DAYTON (US) | 2008-09-09 | — | — | US | disclosed |
| US-7407711-B2 | Non-toxic corrosion-protection conversion coats based on rare earth elements | UNIVERSITY OF DAYTON (US) | 2008-08-05 | — | — | US | disclosed |
| US-7291217-B2 | Non-toxic corrosion-protection pigments based on rare earth elements | UNIVERSITY OF DAYTON (US) | 2007-11-06 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20070149673-A1 | NON-TOXIC CORROSION-PROTECTION PIGMENTS BASED ON MANGANESE | STURGILL JEFFREY A | 2007-06-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20040104377-A1 | Non-toxic corrosion-protection pigments based on rare earth elements | UNIVERSITY OF DAYTON | 2004-06-03 | — | — | US | disclosed |
| US-20040020568-A1 | Non-toxic corrosion-protection conversion coats based on rare earth elements | DAYTON, UNIVERSITY OF | 2004-02-05 | — | — | US | disclosed |
| US-20040016910-A1 | Non-toxic corrosion-protection rinses and seals based on rare earth elements | DAYTON, UNIVERSITY OF | 2004-01-29 | — | — | US | disclosed |
| US-20040011252-A1 | Non-toxic corrosion-protection pigments based on manganese | UNIVERSITY OF DAYTON | 2004-01-22 | — | — | US | disclosed |
| CN-1055468-C | New alkylaminoindane compounds, processes for preparing them and pharmaceutical compositions containing them | ADIR (FR) | 2000-08-16 | — | — | CN | disclosed |
| US-5569669-A | Alkylaminoindane compounds | ADIR ET COMPAGNIE (FR) | 1996-10-29 | — | — | US | disclosed |
| CN-1111620-A | New alkylaminoindane compounds, processes for preparing them and pharmaceutical compositions containing them | ADIR (FR) | 1995-11-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CYP2B6 758/4885CYP1A1 1394/4885CYP1A2 659/4885 |
| US-20140135359-A1 | METHODS OF DESIGNING, PREPARING, AND USING NOVEL PROTONOPHORES | UQCRC2, UQCRC1, TIMM50 | CYP2B6 921/4885CYP1A1 1305/4885CYP1A2 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.